EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Neutrophil-to-lymphocyte ratio predicts infusion-site skin nodules in Parkinson’s disease patients receiving foslevodopa/foscarbidopa subcutaneous infusion

Elena Contaldi, Luca Magistrelli, Silvia Piazza, Arturo Caniglia, Ennio A. Mainardi, Pasquale Giametta, Gianni Pezzoli, Ioannis U. Isaias, Giulia Lazzeri

Journal of Neural Transmission · 2026-10-31

DOI: 10.1007/s00702-026-03301-1 ↗
AbstractBibliografische Angaben

Abstract

Abstract Continuous subcutaneous foslevodopa/foscarbidopa infusion (LDp/CDp-CSI) is an effective treatment for patients with Parkinson’s disease (PD), but infusion-site nodules are a major cause of treatment discontinuation. Systemic inflammation can influence local skin tolerance; however, predictive biomarkers remain unidentified. To evaluate the predictive value of the neutrophil-to-lymphocyte ratio (NLR) for clinically significant infusion-site nodules (PD-CSN) during LDp/CDp-CSI and to establish a clinical management framework to mitigate their development. We prospectively followed 38 patients with PD initiating LDp/CDp-CSI for ≥ 3 months. Baseline immunological data were collected before infusion. A subset of 30 patients was followed for an average of 11 months to identify factors associated with skin nodules at longer follow-up. Nodules were classified by blinded raters. Between-group comparisons, ANCOVA, ROC curve, and Kaplan-Meier analyses were performed. At 3 months, 42% of patients were PD-CSN and showed higher baseline neutrophil counts ( P = 0.030) and NLR ( P = 0.007), with NLR remaining independently associated with nodule status (F = 7.06, P = 0.012). ROC analysis demonstrated acceptable discrimination (AUC = 0.73, P = 0.016). At last follow-up, lower baseline lymphocyte counts ( P = 0.002) and higher NLR ( P = 0.001) were observed in PD-CSN. High baseline NLR predicted earlier nodule onset ( P = 0.001). Despite frequent nodules, multidisciplinary team surveillance, including remote and in-person follow-up, limited treatment discontinuation to 5.3%. Baseline systemic inflammation, reflected by NLR, predicts both the onset and persistence of infusion-site nodules during LDp/CDp-CSI. NLR may serve as a clinically accessible biomarker for early risk stratification. Multidisciplinary surveillance facilitates timely nodule management and enhances treatment adherence.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →